Portfolio Lab

ALPS Medical Breakthroughs ETF

  • ETF
  • Ticker SBIO
  • NYSE

Performance, volatility and drawdowns of ALPS Medical Breakthroughs ETF since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

SBIOGlobal equities (VT)

$10,000 grew to $21,475. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −63.1% in 10/2023, measured from the peak in 02/2021. It took 64 months to get back to the old peak.

Factor profile

Monthly returns 12/2016 to 09/2026, measured against USA. The factors explain 57% of the variation.

Market
0.70
Size
1.29
Value
−0.40
Profitability
−0.51
Low investment
−0.15
Momentum
0.06

How to read this: SBIO moves less than the stock market (USA): when the market rises by 1%, the ETF rises by 0.70% on average. The ETF leans towards small companies, highly valued growth stocks and less profitable companies.

A value of 1 for the market means: when the market rises by 1%, the ETF rises by 1% on average. The other values show the lean towards small, cheaply valued, profitable, conservatively investing and recently strong stocks; bold where it is clear. Calculated with the Fama and French factors and momentum.

Open in factor analysis

Annual returns

Best year 2025 at +55.1%, weakest 2022 at −28.1%. 6 of 9 full years were positive. * partial year.

Similar ETFs

Frequently asked questions

How has SBIO performed since 11/2016?

$10,000 grew to $21,475 by 20 Nov 2026, which is +7.9% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is SBIO?

Volatility was 27.7% per year, measured on monthly returns. The largest decline from a peak was −63.1%, with the low in 10/2023.

How does SBIO compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, SBIO returned +7.9% at 27.7%. The correlation of monthly returns was 0.54; 1 would mean they moved in lockstep.

What does SBIO hold?

SBIO holds 103 positions. The largest are Crinetics Pharmaceuticals, Inc., Apogee Therapeutics, Inc. and CG oncology, Inc.; the 10 largest together make up 31.4% of the fund (holdings as of 31 Aug 2026, according to the fund's filing with the SEC).

Which currency are the figures in?

In US dollars, the currency of the US listing.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

ALPS Medical Breakthroughs ETF (SBIO): Return and risk